Introduction
The p53 transcription factor responds to a variety of stress conditions including oncogene activation, DNA damage and hypoxia. Accumulation and activation of p53 upon such stress triggers growth arrest or apoptosis through transcriptional regulation of specific target genes (see Vousden and Lu, 2002) . This serves to eliminate cells carrying oncogenic lesions or damaged DNA, thus preventing tumor development. Inactivation of p53 by mutation occurs in around half of human tumors. The great majority of mutations are missense point mutations that target the DNA-binding core domain, thereby abolishing specific DNA binding of p53. This prevents p53-dependent transcription and, hence, p53-mediated tumor suppression. The exceptionally high frequency of p53 mutations in human tumors of diverse types makes p53 unique among genes involved in tumor development (see p53.free.fr and www-p53.iarc.fr; Be´roud and Soussi, 1998; Olivier et al., 2002) . Indeed, unbiased sequencing of whole genomes of breast and colon cancers confirmed that p53 is the most commonly mutated gene in these tumors (Sjo¨blom et al., 2006) . Accordingly, p53 is the focus of research aimed at development of novel anticancer drugs. Several approaches that exploit p53 inactivation in tumors for therapy are currently being pursued, such as selective expression of killer genes in cells with nonfunctional p53 or replication-deficient viruses that can propagate only in p53-deficient cells (reviewed in Lane and Lain, 2002; McCormick, 2001) . Wild-type p53 reconstitution by gene therapy has been shown to inhibit tumor growth in clinical trials (reviewed by Wiman, 2006) . However, the absence of efficient delivery systems has precluded systemic administration so far. In addition, the immune response against viral vectors may reduce the clinical utility of gene therapy.
A principally different line of attack on tumors is the rescue of p53 tumor suppressor functions by small molecules. Tumor cells should be particularly sensitive to reconstitution of p53 function as mutations that inactivate p53 and ablate p53-induced apoptosis in response to oncogenic stress have been selected during tumor evolution. Small molecule strategies for restoration of p53 functions in tumors can either target wildtype p53 or mutant p53. In wild-type p53-carrying tumors, the aim is the identification of molecules that can protect p53 from its own cellular destructor Mdm-2 in many types of cancers or from degradation by the human papilloma virus E6 protein in cervical carcinomas (reviewed in Chene, 2003; Zheleva et al., 2003) . In tumors that carry p53 point mutations in the core domain, attempts have been made to restore wild-type functions to mutant p53. Since the first evidence that the cryptic DNA binding of mutant p53 could be restored by phosphorylation or antibody binding (Hupp et al., 1993) , results from several laboratories have provided proof-of-principle for mutant p53 rescue. Specific DNA binding, transcriptional transactivation and, most importantly, the tumor suppressor functions of p53 have been restored by various strategies, including introduction of second-site mutations, antibody binding, short peptides and small molecules.
Advantages of mutant p53 rescue as a therapeutic strategy
Several features of p53 mutations make restoration of wild-type p53 functions to mutant p53 feasible. First, the vast majority of tumor-derived mutations target one domain of the protein, the so-called core domain, which harbors the specific DNA-binding activity. Around 80% of these mutations are missense point mutations resulting in substitution of only one amino-acid residue (see p53.free.fr; www-p53.iarc.fr). The so-called hot spots are residues where mutations occur with unusually high incidence. Substitutions of arginine residues at positions 175, 248, 273 and 282 represent around 20% of all mutations found in tumors. Second, recent structural studies have revealed that the tumor-derived missense mutations in the core domain produce a common effect: destabilization of core domain folding at physiological temperature (for details, see below). This precludes proper orientation of loops and helixes that form the DNA-binding interface and therefore disrupts DNA binding. However, the defect is not irreversible as many mutants can bind DNA at lower temperature. Third, mutant p53 proteins are usually overexpressed in tumors, which is in contrast to other tumor suppressors such as pRb and p16, the inactivation of which in tumors is achieved largely by loss of expression (Nevins, 2001) . Mutant p53 proteins accumulate at high levels in tumor cells mainly due to their inability to upregulate the expression of p53's own destructor Mdm-2 (Midgley et al., 2000) . Heat-shock proteins can probably contribute to mutant protein stabilization as well (Peng et al., 2001) .
Thus, around half of all human tumors overexpress a highly potent tumor suppressor, which is unable to perform its functions because of defects in its folding. Is it possible to reverse these folding defects and restore wild-type functions to mutant p53 in tumors? This would be an extremely efficient strategy for selective elimination of tumor cells, because of the high expression of the target protein in most tumors. A small molecule targeting mutant p53 should not affect wildtype p53 in normal cells because it is already properly folded and because of its low levels owing to continuous degradation by Mdm-2 in the absence of stress. Importantly, tumor cells carrying mutant p53 are likely to preserve intact downstream apoptotic pathways. Finally, owing to constitutive stress signaling in tumor cells, for example oncogene activation, DNA damage and hypoxia, mutant p53 is probably already 'activated' by post-translational modifications and partner proteins, whereas p53 is latent in normal cells in the absence of stress (Figure 1 ). This notion is supported by studies of p53ER TAM knock-in (KI) mice (Christophorou et al., 2005) . This model makes it possible to switch p53 on and off in tissues in vivo. The p53ER TAM fusion protein can be reliably and tightly regulated by 4-hydroxytamoxigen (4-OHT) in vivo, faithfully reproducing various aspects of p53 functions. Since the expressed p53ER TAM protein is functionally competent only in the presence of 4-OHT ligand, the p53ER TAM KI mouse provides an excellent tool for the analysis of p53 reactivation, both in mouse tissues in vivo and in explanted primary cells derived from such tissues in vitro. In the absence of 4-OHT, p53ER
TAM KI mice reproduce a classic p53 knockout phenotype with a high incidence of spontaneous tumors, mainly lymphomas. Systemic administration of 4-OHT to p53ER TAM KI mice rapidly restores p53 functions in all tissues. Notably, restoration of p53 functions in normal tissues is well tolerated in mice and produces no visible toxic effects. This correlates with the absence of p53-induced growth suppression in cultured cells derived from p53ER TAM KI mice upon 4-OHT treatment in vitro. However, restoration of p53 activity by 4-OHT in irradiated cells or in cells expressing oncogenic Ras leads to activation of p53 and its target genes, thus unleashing the p53 growth suppressor function (Christophorou et al., 2005) . These results provide compelling evidence supporting the notion that oncogene expression is required for the functional activity of p53 in cells.
Importantly, recent results obtained using p53ER TAM KI mice demonstrate that re-establishment of active p53 in fully developed radiation-induced lymphomas confers significant tumor suppression (Christophorou et al., 2006) . This indicates that tumor cells carrying oncogenic mutations harbor persistent signals that can be engaged by p53 to suppress tumor outgrowth. Thus, only the environment of cancer cells provide the signals required to unleash p53's tumor suppressor effect. Therefore, restoration of p53 functions by small molecules should have a therapeutic effect at any point of tumor development without harmful effects in normal cells. One can therefore envisage abundant and activated mutant p53 as a 'loaded gun' present in the tumor cells (Selivanova, 2001 ). However, the gun's trigger is locked by a mutation. A small molecule that can reverse the effect of the mutation will unlock the trigger and fire the gun, killing the tumor cells (Figure 1) . Such a molecule would be a most efficient, widely applicable and highly selective anticancer drug.
Structural basis for mutant p53 reactivation
Structural consequences of oncogenic mutations in the p53 DNA-binding domain The cocrystal structure of the wild-type p53 core domain bound to DNA together with more recent nuclear magnetic resonance (NMR) and X-ray studies on tumor-derived core domain mutants have revealed the structural impact of amino-acid residues that are most frequently mutated in human cancers (Cho et al., 1994; Wong et al., 1999; Joerger et al., 2004 Joerger et al., , 2005a Ang et al., 2006) . The so-called DNA contact mutants, for example R273H and R248Q, carry substitutions of residues that directly contact DNA. Structural mutations such as R175H and R249S target residues that are important for the proper orientation of the two loops and loop-sheet-helix motif that form the DNA-binding surface of the core domain.
NMR studies and quantitative assessment of folding and DNA-binding properties of mutant core domain proteins have revealed that the major effect of oncogenic mutations is destabilization of the secondary structure of the core domain at physiological temperature. Mutations result in lowering of the melting temperature by 5-101, which is sufficient to tip the balance towards the unfolded state at physiological temperature (Bullock et al., 1997) . The extent of unfolding varies depending on the site and the nature of the mutation. For example, 99% of the R273H mutant is folded at 371C, whereas only 5% of the F134L mutant remains folded at this temperature (Bullock et al., 2000) . For some mutants, such as G245S, R248Q and R249S, only localized changes have been observed, suggesting that their overall tertiary folds are similar to that of the wild-type protein. Mutations located in the b-sandwich region, such as R175H and R282W, heavily destabilize the secondary structure, resulting in unfolding of 50% of the protein at physiological temperature (for a review, see Joerger et al., 2005a, b) .
Thermodynamic instability correlates with the enhanced kinetics of unfolding at 371C: the heavily destabilized mutants V143A, I195T, C242S and R249S unfold 10 times faster than wild type, whereas less destabilized mutants such as R273H and G245S unfold only slightly faster. Moreover, unfolding is associated with the aggregation of mutant proteins at 371C: the higher the degree of unfolding, the faster the aggregation . Interestingly, mutant p53 proteins are prone to loss of the Zn (2 þ ) atom that is bound to the wild-type core. This also promotes aggregation of mutant p53 (Butler and Loh, 2003) .
High-resolution crystal structures of tumor-derived mutants provide deeper insight into the consequences of mutations. Tumor-derived mutations might result in loss of essential contacts with DNA, distortion of the DNA-binding interface, disruption of core-core interactions and loss of cooperativity of DNA binding, or appearance of large internal crevices or cavities leading to a significant loss of thermodynamic stability (Joerger et al., 2005a (Joerger et al., , b, 2006 Ang et al., 2006) . These findings provide a structural basis for rational design of molecules that can rescue the activity of mutant p53. For example, some mutants can potentially be rescued by a generic stabilizing drug, whereas a mutationinduced crevice represents a potential drug target in other mutants.
In summary, structural studies show that the extent of misfolding differs among mutants; therefore it appears unlikely that different mutants possess a defined alternative fold. Another important prediction from structural studies is that a ligand (i.e. protein, short peptide or small molecule), which binds to the properly folded fraction of the protein, is expected to shift the equilibrium towards the native fold according to the law of mass action. This suggests that a small molecule approach to reverse the effect of p53 mutation could be successfully applied to a wide range of mutant forms.
Biochemical studies on conformational flexibility of the core domain Numerous studies have demonstrated an intrinsic conformational flexibility of wild-type p53 in cells. The epitope recognized by the monoclonal p53 antibody PAb240 is either exposed or masked in cells depending on the growth culture conditions (Milner and Watson, 1990) . PAb240 binds to residues 212-217 in the core domain that are exposed in denatured wild-type p53 (Gannon et al., 1990; Vojtesek et al., 1995) . This epitope is frequently displayed in tumor-derived p53 mutants, usually followed by the loss of reactivity with another conformational core domain-specific antibody, PAb1620. This antibody recognizes a nonlinear epitope in the p53 core domain which is present only in the 'wild-type' active conformation and includes residues R156, L206, R209 and N210 (Cook and Milner, 1990; Wang et al., 2001) . Induction of the PAb240 epitope was shown to occur in embryonic stem cells upon differentiation with a concomitant loss of PAb1620 epitope and functional activity of the protein (Sabapathy et al., 1997) . The mutually exclusive recognition by PAb240 and PAb1620 led to the idea of two alternative conformations: PAb240 þ /PAb1620À 'mutant' nonfunctional p53 and PAb240À/PAb1620 þ 'wild-type' active p53. However, as mentioned above, structural studies do not support the idea of a defined 'mutant' fold. Rather, p53 exists as a set of interconverting conformers. The lack of a rigid structure of the p53 protein may result in a number of p53 conformers displaying different activity, allowing fine-tuning of the p53-mediated biological response depending on the type of stress and cellular context. This notion is supported by recent studies of the solution structure of the p53 core domain that allowed the identification of several structural elements conferring flexibility to the core domain. This suggests that p53 has evolved to be dynamic and conformationally unstable (Canadillas et al., 2006) .
Mutant p53 proteins exhibit greater conformational instability than the wild-type p53. Many mutants display the PAb240 epitope, although the extent of PAb240 reactivity differs between the mutants, as well as the loss of PAb1620 epitope and the ability to bind to the heat-shock proteins Hsp70/Hsp90 (Ory et al., 1994; Gaiddon et al., 2001) . The differential ability to bind PAb240 and heat-shock proteins by p53 mutants lends further support to the idea that mutant proteins expressed in cells display the whole spectrum of unfolded states. It is noteworthy that some mutations can cause only slight changes in p53 conformation, eliminating PAb1620 recognition, but not yet exposing the PAb240 epitope.
Importantly, the defect in folding produced by substitution of one residue does not seem to be irreversible: at least some p53 mutants maintain residual DNA-binding ability. Mutants that fail to bind DNA at 371C can bind at subphysiological temperatures, for example 32 or 251C (Bargonetti et al., 1993; Zhang et al., 1994) , and several mutants can activate transcription from a p53-responsive promoter at 261C (Friedlander et al., 1996; Di Como and Prives, 1998) . In addition, the isolated mutant core domain proteins R245S, R282W, V143A and others were shown to have residual (30-60%) DNA-binding activity at 201C (Bullock et al., 2000) . The transcriptional transactivation activity of at least 10% of p53 mutants reported in p53 databases is temperature-sensitive (Shiraishi et al., 2004) . Thus, many p53 mutants maintain the intrinsic ability to bind DNA.
The temperature sensitivity of DNA binding by p53 mutants is often linked to a temperature-dependent variation in protein conformation. Even one of the most heavily destabilized mutants, R175H, can adopt a native fold at low temperature: R175H protein produced in insect SF9 cells at 251C is predominantly PAb1620 þ / PAb240À, whereas the same mutant produced at 371C is mainly unfolded as it binds PAb240, but not PAb1620 (Cohen et al., 1999) . In conclusion, both biochemical and structural studies suggest that the distortion of mutant p53 core domain folding and defects in mutant p53 DNA binding are not irreversible.
Impact of the N-and C-terminal domains on the folding of the core Accumulating experimental data suggest that the carboxy-and amino-terminal domains are involved in the folding and DNA binding of the core. The last 30 residues of the C-terminal domain were proposed to negatively regulate DNA binding by an allosteric mechanism. This hypothesis was based on the observation that the interaction of p53 with a short oligonucleotide containing a consensus p53-binding site is greatly enhanced either by the deletion of the C-terminal basic region (30 residues) or by binding of the antibody PAb421 to the same region (Hupp and Lane, 1994) . This was confirmed by a study showing that p53 transcriptional activity is activated by PAb421 in cells (Lu and Lane, 1993) . Recent studies have demonstrated that within the context of chromatin or supercoiled DNA, the C-terminal domain may actually facilitate binding of the core to its target DNA sequence by providing an additional anchorage to specific DNA sites via nonspecific DNA binding (Espinosa and Emerson, 2001; McKinney and Prives, 2002; McKinney et al., 2004) .
Along with its effect on DNA binding the C-terminal domain confers conformational instability to the core domain. Substitution of one of the phosphorylation sites in the C terminus, S392E, by mutation mimics constitutive phosphorylation and increases DNA binding and stability of the core (Nichols and Matthews, 2002) . Binding of the bacterial heat-shock protein DnaK or PAb421 antibody to the C-terminal basic region, and to a lesser extent deletion of this region, increases the resistance of the core domain to thermal denaturation as assessed by the retention of PAb1620 epitope upon heating to 371C (Hansen et al., 1996) . The N-terminal domain also appears to affect the folding of the core: the antibodies DO1 and PAb1801 that detect N-terminal epitopes (residues 20-25 and 46-55, respectively) protect p53 from thermal denaturation and inactivation of DNA binding at 371C (Friedlander et al., 1996; Hansen et al., 1996) . Some mutant p53 proteins were shown to bind and inactivate the p53 homologs p73 and p63 (Strano et al., 2000; Gaiddon et al., 2001) . Interestingly, p73 binding is influenced not only by the nature of the mutation but also by a polymorphism in p53 codon 72, which is either Arg or Pro. Mutant p53 binding to p73 is enhanced when codon 72 encodes Arg (Marin et al., 2000) . As a conformational change in the core has a major impact on binding to p73 (Strano et al., 2000; Gaiddon et al., 2001; Bensaad et al., 2003) , these results suggest that the Pro/Arg residue at position 72 can affect the folding of the core. Yet another study has supported a role of the Pro-rich domain (residues 62-93) in core domain folding: deletion of this region resulted in attenuation of DNA binding similar to the effect produced by certain tumor-derived point mutations in the core (Roth et al., 2000) . In addition, a synthetic peptide spanning the Pro-rich region was shown to affect the DNAbinding properties of the core domain (Mu¨ller-Tiemann et al., 1998) .
Cross-talk between the different p53 domains has also been indicated in earlier studies, showing that destabilization of the core by mutation (R273H) inhibits the transactivation activity of the N-terminal domain (Fields and Jang, 1990) . More recent NMR studies confirm that the N-and C-terminal domains have an impact on the thermodynamic instability of the p53 tetramer (Bell et al., 2002) .
However, until recently it has remained unclear whether and exactly how the cross-talk between p53 domains occurs. Although the X-ray structures of p53 domains, including the core domain, the oligomerization domain and short stretches from both the C terminus and the N terminus have been reported, the overall packing and mutual orientation of domains in p53 tetramer is still unknown. The structure of the fulllength p53 protein presents a formidable challenge to structural biologists and has eluded numerous attempts of crystallization, largely because of the intrinsic flexibility of the protein, leading to its aggregation at high concentration.
The first structure of the intact full-length p53 tetramer has been solved at 13.7 Å resolution using cryoelectron microscopy (cryoEM) (Okorokov et al., 2006) . According to the proposed model, based on three-dimensional reconstruction of tetrameric p53, the p53 molecule has a D2 symmetry and has a shape of a hollow skewed cube, in which the upper and lower layers are represented by dimers which are rotated approximately 601 with respect to each other (Figure 2 ). The most surprising finding is that the interaction between residues 323-363 of the C termini, previously observed using isolated C-terminal proteins, is suppressed and replaced by N/C-terminal interactions forming a dimer. Further, tetramers are formed via the contacts between core domains and N/C nodes in close proximity to the core domains (Figure 2 ). This provides a framework for understanding existing biochemical data on the effect of the N and C termini on the conformation and DNA binding of the core domain. Since the N/C nodes of each dimer are in direct contact with the core domains of another dimer, any modification of the N or C termini, for example phosphorylation, acetylation, antibody binding or small molecules, may affect the core, stabilizing and/or shifting the equilibrium to one state or another. Further structural studies of the full-length tetramer are required to understand the exact nature and consequences of the interactions between the p53 domains.
One important point that emerges from the studies mentioned above is that the binding of ligand(s) to the N-or C-terminal regions of the p53 protein can probably stabilize the conformation of the core domain, and therefore, such ligands could be useful in therapeutic strategies aimed at stabilization of mutant p53 conformation.
Current strategies for mutant p53 rescue
Reactivation of mutant p53 by structural manipulations and peptides A significant proportion of mutants, including both DNA contact and structural hot-spot mutants such as R273 H, R273C, R248Q, R282W and G245S, can be activated for DNA binding by C-terminal manipulations, for example binding of PAb421 antibody, truncation or phosphorylation (Hupp et al., 1993; Halazonetis and Kandil, 1993; Niewolik et al., 1995 ; for a review, see Selivanova and Wiman, 2001) . Moreover, the transcriptional transactivation function of the common mutant R273H was restored by microinjection of PAb421 antibody or PAb421-derived Fv fragments in tumor cells (Abarzua et al., 1995; Caron de Fromentel et al., 1999) . In addition, several monoclonal antibodies that recognize N-terminal epitopes can partially rescue the DNA binding of p53 mutants (Cohen et al., 1999) . Finally, deletion of N-terminal residues 13-16 has been found to reverse the temperature-sensitive phenotype of the mouse mutant A135V (Liu et al., 2001) . These results, taken together with the proposed new structure of the p53 tetramer discussed above, support the idea that regulatory regions at the N-and C-terminal ends of the protein are suitable targets for the development of p53-reactivating molecules. As both N-and C-terminal manipulations can rescue several different mutants, these data indicate that a generic approach for mutant p53 reactivation is feasible. In other words, each individual mutation will not require its own unique reactivation strategy.
Rational design and genetic selection has allowed the identification of secondary suppressor mutations in the core domain that rescue the DNA binding, transcriptional activity and in some cases, the growth suppressor function of mutant p53 (Wieczorek et al., 1996; Brachmann et al., 1998; Nikolova et al., 2000) . The major effects of second-site mutations include introduction of additional DNA contacts, correction of local distortions and increase of overall stability of the core. These studies have established the important concept that a structural defect conferred by a p53 core domain mutation can be fixed by manipulations outside the mutation site itself.
A synthetic peptide derived from the p53 C-terminal domain (peptide 46) was shown to restore the specific DNA binding and transcriptional transactivation function of several hot-spot mutant p53 proteins and rescue the function of endogenous mutant p53 proteins resulting in growth inhibition and cell death by apoptosis (Selivanova et al., 1997; Kim et al., 1999) . The observation that C-terminal peptides can restore the DNA-binding activity to isolated core domain proteins indicated that it might directly affect the p53 domain where tumor-derived mutations are clustered. It was hypothesized that C-terminal peptides reactivate mutant p53 through stabilization of the core domain folding and/or establishment of novel DNA contacts (Abarzu´a et al., 1995; Selivanova et al., 1997 Selivanova et al., , 1998 Selivanova et al., , 1999 . These findings provided proof-of-principle for functional restoration of tumor-derived mutant p53 proteins by small molecules. Recent in vivo studies have demonstrated that treatment of peritoneal carcinomas and lymphomas with cell-penetrating C-terminal peptides can activate endogenous mutant p53, resulting in disease-free animals and significantly increased lifespan (Snyder et al., 2004) .
The first rational design of a molecule capable of stabilizing p53 core domain folding was undertaken by Fersht and colleagues. The idea behind this approach is that a ligand that binds with higher affinity to the properly folded state of p53, will shift the equilibrium of the mutant core conformation towards this state. An important requirement is that ligand binding should not interfere with specific DNA binding. A short peptide derived from the p53-interacting protein ASPP (previously referred to as 53BP2) (Samuels-Lev et al., 2001) served as a basis for the design of such a ligand. ASPP is a p53-binding protein that interacts with the core domain and enhances p53-dependent transactivation, specifically stimulating the apoptotic function of p53 (Vives et al., 2006) . A nine-residue peptide, CDB3, was designed based on the crystal structure of the complex between the p53 core and ASPP/53BP2 (Gorina and Pavletich, 1996) . NMR provided solid evidence that CDB3 binds to the core domain and induces the refolding of mutant p53 core domain proteins (Friedler et al., 2002) . In vitro studies showed that CDB3 restores sequence-specific DNA binding to various p53 mutants, including the highly destabilized I195T mutant. A chaperone mechanism was invoked by the authors: core-stabilizing factors like the CDB3 peptide probably have to bind p53 during or immediately after biosynthesis to stabilize mutant p53 in an active conformation before rapid unfolding of the mutant protein takes place; after that, CDB3 can be replaced by tighter binding cognate DNA (Friedler et al., 2002) . CDB3 can enter cells and bind p53 in the context of cellular proteins. It restores the PAb1620 þ conformation and transcriptional activity of two hot-spot p53 mutants, R273H and R175H, in human tumor cells (Issaeva et al., 2003) . Interestingly, CDB3 induces accumulation of both wild-type and mutant p53 in cells. Although CDB3 does not trigger a complete biological response, it can serve as a lead for the further development of p53-reactivating molecules.
p53 core domain stabilization may also be mediated by binding to cellular chaperone proteins. p53 can bind to the chaperone proteins Hsp40, Hsp70 and Hsp90 (Walerych et al., 2004) . Unfolded mutant p53 binds Hsp70 with higher affinity than the wild-type protein (Rudiger et al., 2002) . This has led to the idea that binding of Hsp proteins stabilizes p53 in an unfolded conformation and therefore, disruption of Hsp binding to mutant p53 should rescue p53 conformation. Several antitumor fungal antibiotics including geldanamycin have been shown to inhibit Hsp90-dependent unfolding of p53 (Blagosklonny et al., 1996) . Compounds targeting Hsp90 are already undergoing clinical trials (reviewed by Sharp and Workman, 2006) .
Small molecules that target mutant p53
The structural studies and work on short peptides discussed above have clearly demonstrated that mutant p53 proteins can be reactivated with regard to both DNA binding, transcriptional transactivation and induction of apoptosis in human tumor cells. In attempts to exploit this knowledge for development of novel anticancer drugs, screening efforts have been conducted with the aim of identifying small molecules that reactivate mutant p53 with similar or higher efficiency than for example the p53-derived C-terminal peptide. Small molecules offer certain important advantages as therapeutic agents over peptides and larger macromolecules. Most importantly, they are suitable for largescale GMP synthesis and can potentially be used for systemic treatment, for example intravenous or oral administration. Systemic therapy is critical for efficient treatment of metastases in patients with disseminated tumors. This is particularly important as this group of patients generally has the lowest survival and thus represents the greatest challenge for therapy.
Screening for mutant p53 reactivating compounds has been carried out using either protein assays or cellular assays. Protein assays may enable the identification of compounds with a defined molecular mechanism, but such hits may not necessarily be able to enter cells and/ or may be too toxic owing to additional protein targets or induction of DNA damage. Cellular assays, on the other hand, are likely to yield hits with the desired biological effect, such as cell death by apoptosis, but investigators may face difficulties with elucidation of the exact molecular mechanism.
Novel compounds targeting mutant p53 have been identified using both types of screening assays.
CP-31398 was identified by screening for molecules that protect the isolated p53 core domain protein from thermal denaturation, as assessed by maintenance of PAb1620 reactivity upon protein heating (Foster et al., 1999) . In contrast, PRIMA-1 and MIRA-1 were identified in a cellular screening for compounds that induce apoptosis selectively in human tumor cells expressing exogenous mutant p53 (Bykov et al., 2002a (Bykov et al., , 2005b . The compounds were shown to rescue wild-type conformation of mutant p53 proteins in vitro and induce expression of p53 target genes such as p21, MDM2 and/ or PUMA. Moreover, both CP-31398 and PRIMA-1 can inhibit tumor growth in vivo in mice (for a review, see Bykov et al., 2003) .
The mechanism of action of CP-31398 remains unclear. NMR studies failed to detect any binding of CP-31398 to the p53 core domain . Interestingly, CP-31398 increases the levels of wild-type p53 protein in cells by preventing its ubiquitination independently of Mdm-2 and p53 phosphorylation (Luu et al., 2002; Takimoto et al., 2002; Wang et al., 2003) . CP-31398 affects gene expression and induces cell death both in a p53-dependent and -independent manner (Takimoto et al., 2002; Wischhusen et al., 2003; Wang et al., 2003) . Thus, it appears that CP-3138 has other cellular targets than p53 that may account for its cellular toxicity.
PRIMA-1 (for p53 reactivation and induction of massive apoptosis), the methylated analog PRIMA-1MET and MIRA-1 (for mutant p53 reactivation and induction of rapid apoptosis) have similar activity profiles (Bykov et al., 2002a (Bykov et al., , b, 2005a ). Yet they are structurally unrelated and presumably affect mutant p53 through different mechanisms. So far, direct binding to mutant p53 has not been unequivocally demonstrated. Further studies using NMR, X-ray crystallography and/ or mass spectrometry are needed to resolve this issue. An alternative mechanism could be targeting of cellular proteins that in turn bind p53 and restore its conformation and function. Indeed, PRIMA-1 induces expression of heat-shock protein 90 (Hsp90) and enhances its binding to mutant p53, suggesting that Hsp90 mediates mutant p53 refolding (Rehman et al., 2005) . Moreover, PRIMA-1MET triggers redistribution of mutant p53 to nucleoli, along with three other promyelocytic leukemia protein (PML) body-associated proteins, PML, cAMPresponsive binding protein (CBP) and heat-shock protein 70 (Hsp70) (Ro¨kaeus et al., 2006) . PRIMADead, an inactive structural analog, failed to induce nucleolar redistribution of mutant p53 and other PML body-associated proteins, consistent with the notion that nucleolar translocation and perhaps interaction with Hsp70 and other PML body proteins plays a role in reactivation of mutant p53. PRIMA-1 may in fact induce apoptosis via multiple pathways, as it can also trigger mutant p53-dependent apoptosis in the absence of transcription or de novo protein synthesis, or even a cell nucleus (Chipuk et al., 2003) . This notion is further supported by studies showing that PRIMA-1 induces apoptosis via the c-Jun-NH2-kinase (JNK) pathway (Li et al., 2005) .
The effects of PRIMA-1 on mutant p53 are clearly different from those of CP-31398 and CDB3. Whereas CP-31398 confers protection from unfolding at physiological temperature, PRIMA-1 converts already unfolded p53 into an active form independently of protein synthesis (Bykov et al., 2002a) . Furthermore, PRIMA-1 does not activate wild-type p53, in contrast to both CP-31398 (see above) and CDB3 (Issaeva et al., 2003) , and causes a decrease in the overall level of p53 in cells.
The ability of compounds like CP-31398 and PRI-MA-1 to rescue mutant p53 suggests that they may increase sensitivity of tumor cells to chemotherapeutic drugs that are preferentially cytotoxic for tumor cells carrying wild-type p53. This idea has been confirmed in vitro and in vivo in several studies. Synergy has been observed between CP31398 and adriamycin or cisplatin (Takimoto et al., 2002) and between PRIMA-1MET and adriamycin, cisplatin or fludarabine (Nahi et al., 2004; Bykov et al., 2005a) . The synergy could result from enhanced expression of mutant p53 induced by chemotherapeutic drugs (Bykov et al., 2005a) . This indicates that PRIMA-1 may synergize with any agent that increases expression of mutant p53 in tumor cells. Clearly, the observed synergy may have important implications for anticancer therapy in the future, as combination treatment may allow lower doses of conventional chemotherapy and therefore less severe side effects.
The list of mutant p53-targeting small molecules also includes the aminothiol WR1065, a derivative of the cytoprotective drug amifostine that protects normal cells from the toxic effects of irradiation through free-radical scavenging and probably other unknown mechanisms without affecting the killing of tumor cells. WR1065 can at least partially restore wild-type conformation to the temperature-sensitive V272M p53 mutant at 371C, stimulate its DNA binding activity and induce expression of the p53 target genes p21, GADD45 and MDM2, leading to cell-cycle arrest in G1 (North et al., 2002) . WR1065 affects wild-type p53 as well; this effect involves the JNK pathway and DNA damage-independent p53 phosphorylation and stabilization. Moreover, WR1065-mediated activation of p53 relies, at least in part, on its ability to reduce thiol groups in p53 (Pluquet et al., 2003) .
Redox effects are apparently also involved in the action of MIRA-1 and related compounds. All MIRA compounds contain a maleimide group that could potentially react with thiol and amino groups in proteins. Interestingly, a reactive 3-4 double bond in the maleimide group seems to be required for the effect on mutant p53 (Bykov et al., 2005b) . Human p53 contains 10 cysteine residues, all of which reside in the core domain, and it is well established that p53 is subject to redox regulation (Buzek et al., 2002; Seo et al., 2002) . Thus, it is conceivable that covalent modification of cysteine residues could have a role in conformational rescue and restoration of p53 functions. Modification of cysteine residues in the mutant p53 core could inhibit intramolecular or intermolecular disulfide bond formation, which might promote proper core domain folding and/or prevent protein aggregation. Further studies should address whether covalent modification of thiol groups in the core domain may stabilize mutant p53.
Screening for identification of novel mutant p53-targeting compounds Although several low molecular compounds that reactivate mutant p53 have been identified during recent years, it is clearly important to perform additional screens of chemical libraries in order to identify compounds with even higher potency and selectivity for mutant p53-expressing cells. Cellular screening assays should aim at the identification of compounds that elicit the most desired outcome, that is, cell death by apoptosis. To allow a more precise analysis of the molecular mechanism, such cellular assays can be combined with an analysis of p53-dependent transcription using a p53 reporter system, for example luciferase or GFP, in the same cells. This may enable the identification of two distinct classes of compounds that target mutant p53-expressing cells: those that act through restoration of p53-dependent transcription and those that trigger p53-dependent apoptosis via transcription-independent mechanisms. This type of screening strategy was recently used to identify a series of compounds that trigger a p53 response in both p53 null and mutant p53-carrying colorectal carcinoma cells and inhibit tumor growth in vivo (Wang et al., 2006) .
To increase the screening throughput, a first round of screening should use cells carrying inducible exogenous mutant p53 only, and aim at the identification of potent inducers of apoptosis, preferably at the nM range. In the next screening step, identified compounds can be tested for mutant p53 selectivity using the same cells lacking mutant p53 expression. The effect of the identified compounds should also be tested in cells carrying endogenous mutant p53. In this case, the effect should be compared with the effect in the same cells upon silencing of mutant p53 expression by siRNA using an inducible knockdown system. In parallel, screening of chemical libraries should also be carried out using protein-based assays. Since misfolded mutant p53 does not bind specifically to DNA and fails to bind PAb1620 antibody, assays based on rescue of DNA and/or PAb1620 antibody binding could be designed and used for high-throughput screening. Hit molecules should be further tested in various cellular assays to confirm a mutant p53-dependent biological effect. Regardless of the type of assay, the mutant p53-dependent antitumor efficacy of identified hits should be assessed in vivo in suitable mouse tumor models.
Concluding remarks
Mutant p53 reactivation by small molecules is a rapidly evolving approach with great potential for the development of novel anticancer drugs. Inactivation of the p53 pathway is most likely an universal feature of tumor cells. Hence, p53-reactivating molecules should specifically affect tumor cells, as the p53 pathway is intact in normal cells. According to this concept, there is no need to target and reconstitute multiple deficient pathways in the tumor cells; reconstitution of the p53 pathway will be sufficient to trigger apoptosis. Cellular stress in the form of oncogene activation, DNA damage and hypoxia will provide critical constitutive signaling that cooperates with mutant p53 reactivation and sensitizes to p53-induced apoptosis.
An anticipated problem is development of resistance to therapy due to loss of mutant p53 expression in tumors or ablation of downstream effectors in the p53 pathway. Resistance through clonal selection is a fundamental problem in essentially all anticancer therapy. The observed synergistic effects between currently used chemotherapeutic drugs and novel compounds like PRIMA-1 suggest that combination treatment that targets multiple cellular pathways simultaneously will be a useful strategy for overcoming resistance to mutant p53-reactivating drugs.
Although the effect of identified mutant p53-targeting molecules on cell growth and survival are relatively well characterized, their exact mechanisms of action remain poorly understood. As discussed above, restoration of wild-type p53 functions may involve direct binding of a low molecular weight compound to mutant p53 in a manner that promotes correct folding of at least a fraction of mutant p53 protein molecules in the cell (Figure 3) . Alternatively, mutant p53-reactivating molecules could act indirectly in various ways (Figure 4) . Elucidation of the exact molecular mechanisms behind mutant p53 reactivation by novel compounds is an important goal. This will require further structural studies by NMR and other techniques, as well as global analysis of gene expression patterns by microarrays and proteomics.
The successful identification of p53-targeting small molecules during recent years should not discourage Figure 3 Proposed mechanism for targeting mutant p53-carrying tumor cells by a small molecule that binds directly to mutant p53. Such a compound may restore both p53-dependent transcription and p53-mediated transcription-independent effects, resulting in massive apoptosis and elimination of the tumor.
Reactivation of mutant p53 G Selivanova and KG Wiman investigators from initiating screening of chemical libraries with the aim of identifying novel molecular scaffolds for targeting the p53 pathway in human tumors. The molecules identified so far may prove unsuitable for clinical application for many reasons, including problems related to potency and toxicity. Further screening will increase the odds of finding compounds with robust clinical effect and low toxicity. The impressive body of information about the structure of wild-type p53 and the structural consequences of p53 mutations, along with improved tools for screening and drug development, will facilitate the design of additional mutant p53-targeting compounds in the future, many of which may act through entirely novel mechanisms. Thus, mutant p53 reactivation as a field is likely to provide both novel leads for drug development and important new insights into p53 function and regulation. 
